MAPRE3 and cancer: Genomic alterations of MAPRE3 (encoding EB3) and its expression by RNA-seq did not correlate with overall survival outcomes of cancer patients across The Cancer Genome Atlas (Supplementary Fig. 2C), suggesting that EB3 itself is not a major driver of disease progression.